Go Deep
Harvard Bioscience, Inc.
Harvard Bioscience, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 11,443 | -3.6 | 5.10 | 5.96 | 787.08 |
| Oct 2026 | 11,627 | -3.5 | 4.96 | 5.96 | 766.24 |
| Oct 2026 | 11,627 | -3.5 | 4.96 | 5.96 | 767.06 |
| Oct 2026 | 11,418 | -3.6 | 5.12 | 5.96 | 790.77 |
| Oct 2026 | 11,292 | -3.7 | 5.21 | 5.96 | 803.00 |
| Oct 2026 | 11,418 | -3.6 | 5.12 | 5.96 | 787.22 |
| Oct 2026 | 11,510 | -3.6 | 5.05 | 5.96 | 780.06 |
Harvard Bioscience, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 22,727,000.0 | 20,755,000.0 | 23,735,000.0 | 20,591,000.0 |
| Net Profit | -2,910,000.0 | -3,424,000.0 | -2,847,000.0 | -1,231,000.0 |
| EPS | -0.6 | -0.8 | -0.6 | -0.3 |
Harvard Bioscience, Inc. Revenue & Profit: Last 4 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Revenue | 86,550,000.0 | 94,135,000.0 | 112,250,000.0 | 113,335,000.0 |
| Net Profit | -56,700,000.0 | -12,405,000.0 | -3,415,000.0 | -9,516,000.0 |
| EPS | -12.8 | -2.8 | -0.8 | -2.3 |
Harvard Bioscience, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 80,071,000.0 | 126,644,000.0 | 137,366,000.0 | 145,360,000.0 | — |
| Total Liabilities | 66,337,000.0 | 63,304,000.0 | 64,292,000.0 | 73,140,000.0 | — |
| Total Equity | 13,734,000.0 | 63,340,000.0 | 73,074,000.0 | 72,220,000.0 | — |
Owes vs Owns
Harvard Bioscience, Inc. owed $0.90 for every $1 it owned in Jun 2026, up from $0.50 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.90× | 0.83× | 0.50× | 0.47× | 0.50× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Harvard Bioscience, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 10.8%Receivables 20.0%Inventory 26.0%Fixed assets (tangible) 14.9%Intangible assets 21.5%Other assets 6.8%
How it's funded — Dec 2025
Short-term debt 1.9%Long-term debt 44.8%Payables 4.6%Other liabilities 31.6%Shareholders' equity 17.2%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 8.6 | 4.1 | 4.3 | 4.5 |
| Receivables | 16.0 | 14.9 | 16.1 | 16.7 |
| Inventory | 20.8 | 23.2 | 24.7 | 26.4 |
| Fixed assets (tangible) | 12.0 | 11.2 | 8.8 | 9.2 |
| Intangible assets | 17.2 | 67.5 | 73.1 | 77.3 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 5.5 | 5.7 | 10.4 | 11.3 |
| Liabilities & equity | ||||
| Short-term debt | 1.5 | 37.0 | 5.9 | 3.8 |
| Long-term debt | 35.9 | 6.4 | 30.7 | 43.0 |
| Payables | 3.7 | 4.8 | 5.6 | 6.4 |
| Other liabilities | 25.3 | 15.2 | 22.2 | 19.9 |
| Shareholders' equity | 13.7 | 63.3 | 73.1 | 72.2 |
| Net tangible assets | -3.5 | -4.1 | -0.0 | -5.1 |
Harvard Bioscience, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | 6,729,000.0 | 1,440,000.0 | 14,028,000.0 | 1,152,000.0 | — |
| Investing Activities | -1,863,000.0 | -1,344,000.0 | -1,799,000.0 | -1,590,000.0 | — |
| Financing Activities | -1,291,000.0 | -131,000.0 | -12,134,000.0 | -2,837,000.0 | — |